Measurable indicators in diabetes subjects were influenced by the administration of Sabinsa’s Curcumin C3 Complex/BioPerine combination
Two recently published papers have reported the results of a clinical trial examining the impact of Sabinsa’s Curcumin C3 Complex/BioPerine combination on diabetic subjects.
In a randomised, double-blind placebo-controlled trial involving a total of one hundred type-2 diabetes subjects treated with C3 Complex/BioPerine combination (500mg/5mg respectively as daily dose) or placebo for three months, the researchers found that C3 Complex/BioPerine combination improved the glycemic parameters such as glucose concentration and Hb1Ac in the blood.
Decrease in both these parameters indicated a positive response to C3 Complex/BioPerine by diabetic subjects. Also, the levels of C-peptide, an indicator of the amount of insulin produced, also registered an increase in the subjects receiving the supplement over the placebo-receiving subjects.
Hepatic health in the supplement-receiving subjects also improved as shown by the ALT and AST parameters.
In addition, improved function of the beta cells of the pancreas, the site of insulin production, was indicated by HOMA-β values measured.
The authors also noted an increase in the values of anti-inflammatory adiponectin, an adipokine again connected with glucose maintenance and insulin sensitivity. This increase was observed along with a decreasing leptin/adiponectin ratio and lower values of leptin. The leptin/adiponectin ratio has been recognised as an indicator of atherosclerosis with lower values as a healthy indicator.
The trial also indicated lower levels of pro-inflammatory cytokine TNFα in C3 Complex/BioPerine group.
Commenting on the results, Sabinsa founder Dr Muhammed Majeed said, “While we’ve known that our ingredients hold the keys to good health, work in this area is particularly encouraging given the prevalence and growth of Type 2 diabetes worldwide.”